<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2591">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217396</url>
  </required_header>
  <id_info>
    <org_study_id>IRCCS Neuromed</org_study_id>
    <nct_id>NCT03217396</nct_id>
  </id_info>
  <brief_title>Biomarkers of Synaptic Damage in Multiple Sclerosis</brief_title>
  <official_title>Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuromed IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS Multimedica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuromed IRCCS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective and retrospective cohort study of about five years will be performed on blood&#xD;
      and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within&#xD;
      the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as&#xD;
      Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD),&#xD;
      and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical&#xD;
      reasons will be recruited As control groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood and cerebrospinal fluid samples will be subjected to the procedures required for the&#xD;
      isolation of the different components immediately after the withdrawal. Subsequently, the&#xD;
      levels of microRNAs, cytokines, chemokines, cell growth factors, neuronal damage markers&#xD;
      (tau, phosphorylated and truncated tau, neurofilaments) and mitochondrial (lactate) and free&#xD;
      d-amino acids (Objective 1) will be determined. Furthermore, synaptic alterations will be&#xD;
      evaluated in the ex vivo chimeric model of MS, using the patch-clamp technique (Objective 2).&#xD;
      Genotyping studies will be conducted in order to identify single nucleotide polymorphisms&#xD;
      (SNPs) in coding and / or regulating regions of genes (microRNAs or proteins) involved in&#xD;
      alterations of the synaptic transmission of MS and its murine experimental model (i.e.&#xD;
      SLC1A3, NGFB, PDGFA, etc.), which correlate with specific clinical parameters (i.e. EDSS,&#xD;
      BREMS, disease progression index, MS type, disease activity, etc.) and with the levels of&#xD;
      potential biomarkers identified&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 22, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of predictive biomarkers of SM using an ex vivo chimeric model</measure>
    <time_frame>September 01 2020</time_frame>
    <description>CSF concentrations of: neurofilaments, beta amyloid, tau protein, inflammatory cytokines and microRNAs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of new therapeutic targets in MS.</measure>
    <time_frame>September 01 2020</time_frame>
    <description>CSF concentrations of: neurofilaments, beta amyloid, tau protein, inflammatory cytokines and microRNAs</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Parkinson Disease</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>multiple sclerosis patients</arm_group_label>
    <description>lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neurodegenerative disease patients</arm_group_label>
    <description>lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control subjects</arm_group_label>
    <description>lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lumbar puncture</intervention_name>
    <description>lumbar puncture performed to detect OCB for diagnostic purposes</description>
    <arm_group_label>control subjects</arm_group_label>
    <arm_group_label>multiple sclerosis patients</arm_group_label>
    <arm_group_label>neurodegenerative disease patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients recruited within the Neurology Unit, IRCCS Neuromed. Subjects with other chronic&#xD;
        neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease&#xD;
        (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and /&#xD;
        or lumbar puncture for clinical reasons will be recruited as control group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients (age between 18 and 65 years)&#xD;
&#xD;
          2. Diagnosis of MS in accordance with McDonald's (2010 rev) criteria,&#xD;
&#xD;
          3. EDSS between 0 and 5.5 (included),&#xD;
&#xD;
          4. Patients able to provide informed consent to participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide informed written consent&#xD;
&#xD;
          2. Altered basal blood count&#xD;
&#xD;
          3. Pregnancy or lactation&#xD;
&#xD;
          4. Contraindications for the execution of magnetic resonance imaging with gadolinium&#xD;
&#xD;
          5. Significant clinical conditions in addition to SM or other chronic neurodegenerative&#xD;
             diseases including latent viral infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diego Centonze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Neuromed</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diego Centonze, MD</last_name>
    <phone>+39 3934444159</phone>
    <email>centonze@uniroma2.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario Stampanoni Bassi, MD</last_name>
    <phone>+39 3460181370</phone>
    <email>mario_sb@hotmail.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Neuromed</name>
      <address>
        <city>Pozzilli</city>
        <state>Isernia</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Passarelli</last_name>
      <phone>+39 0865.915217</phone>
      <email>direzionescientifica@neuromed.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>October 27, 2022</last_update_submitted>
  <last_update_submitted_qc>October 27, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuromed IRCCS</investigator_affiliation>
    <investigator_full_name>Mario Stampanoni Bassi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>synaptic plasticity</keyword>
  <keyword>neuroinflammation</keyword>
  <keyword>neurodegeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

